Pharmiweb.com RSS Feeds 
PharmiWeb Candidate Blog
Features
19 Apr 04
DailyUpdates 19th April: NSAIDs have shown promising activity in the prevention and possible treatment of cancer. The French pharmaceutical NicOx has successfully improved both the safety and efficacy of NSAIDs by attaching a nitric oxide donor group to various NSAIDs. In a recent study nitrosulindac has been demonstrated to act as an effective and selective cytotoxic and antiproliferative agent against bladder cancer cells. The efficacy of nitrosulindac was considerable better than sulindac.
LeadDiscovery
16 Apr 04
DailyUpdates 16th April: RNA interference is emerging as a major tool to help researchers identify new therapeutic targets. Novartis researchers have recently used this technology to underline the role that the ligand activated cation-channel, P2X3 plays in neuropathic pain. This study also demonstrates the therapeutic potential of P2X3 gene silencing in the treatment of this major unmet area of analgesia.
LeadDiscovery
16 Apr 04
Pharmaceutical Education Associates is proud to present:
The Inaugural Prodrugs: Effective Solutions for Solubility, Permeability, and Targeting Challenges Conference, June 28-29, 2004 at The Union League, Philadelphia, PA. . Please visit http://www.pharmedassociates.com/ for more details, or call 800-686-2276.
Jennifer McGinnis
14 Apr 04
DailyUpdates 14th April: Neuropathic pain affects 26 million patients including a sub-population of cancer patients being treated with cytotoxics. McGill researchers have published the results of a study looking at neuropathic pain in various strains of mice. These data show that neuropathic pain has a genetic component suggested to be equally relevant to paclitaxel and surgically-induced pain. The study also advances the use of paclitaxel-induced hyperalgesia as a model for the development o
LeadDiscovery
13 Apr 04
DailyUpdates 13th April: According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. Approximately 10-15% of these patients suffer type 1 diabetes. Novo Nordisk have shown that their Kir6.2/SUR1 channel opener, NN414 is able to preserve beta-cell function and reduction of insulitis presumable through the induction of "beta-cell rest".
LeadDiscovery
08 Apr 04
DailyUpdates 8th April: An estimated 5 million individuals suffer from rheumatoid arthritis in the Western world. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, their clinical benefit for rheumatoid arthritis often diminishes with time. This, the severe rebounds observed following the withdrawal of corticosteroids, and long-term systemic side effects associated with corticosteroids limits their use in the treatment of rheumatoid arthritis. Rese
LeadDiscovery
07 Apr 04
DailyUpdates 7th April: A recent survey of community-dwelling women in France, Germany, Spain and the UK found that 35% women suffer urinary incontinence, the most prevalent form of which was stress urinary incontinence. The findings also revealed that two-thirds of women affected with urinary incontinence never consulted a health care professional for treatment. The perceived and real lack of pharmaceutical options for the treatment of stress urinary incontinence is a major factor contributing
LeadDiscovery
06 Apr 04
DailyUpdates 6th April: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. In a recent study Glasgow Royal Infirmary researchers report that intensive treatment slowed progression of renal disease within 2 years in patients with established diabetic nephropathy and predict that this approach may delay the onset of dialysis b
LeadDiscovery
05 Apr 04
DailyUpdates 5th April: There is growing evidence of a link between type-2 diabetes/obesity and Alzheimer disease. Researchers now report that diet-induced insulin resistance increases beta amyloid generation, amyloid plaque burden in the brain and behavioural impairment in a model of Alzheimer disease.
Leaddiscovery
02 Apr 04
DailyUpdates 2nd April: There is growing evidence that type-2 diabetes is a risk factor for Alzheimer disease. In their April American Journal of Pathology article Brigham and Women's Hospital researchers add further evidence to support defects in insulin-degrading enzyme activity as a potential cause of this phenomenon. This and similar data argues for the development of cross-indication treatments of type-2 diabetes and Alzheimer disease and GSK-3 inhibitors may fit the bill.
LeadDiscovery
01 Apr 04
DailyUpdates 1st April: Osteoarthritis is the most common form of arthritis and is estimated to affect over 73 million people in the seven major pharmaceutical markets. Disease modifying osteoarthritis drugs (DMOADs) currently represent the ‘holy grail’ in the treatment of osteoarthritis. The Group for the Respect of Ethics and Excellence in Science (GREES) have now published recommendations on the clinical development of DMOADs.
LeadDiscovery
31 Mar 04
DailyUpdates 31st March: Bipolar disorder affects over 2 million people in the US alone. Lithium, which inhibits inositol monophosphatase, has long been a first line mood stabilizer used in the treatment of this condition. Merck & Co have now developed a new cell-based HTS assay to identify novel inositol monophosphatase inhibitors which will hopefully lead to improved treatments of bipolar disorder.
LeadDiscovery
30 Mar 04
DailyUpdates 30th March: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. Intensive glycemic control prevents or retards microalbuminuria, an early sign of nephropathy in patients with type 2 diabetes and in a recent study Japanese researchers compare two different classes of oral antidiabetic drugs with respect to their e
LeadDiscovery
29 Mar 04
Overactive bladder, a condition associated with a variety of other pathologies affects over 17 million Americans and costs the US over $12 billion per year. Current treatments focus on the muscarinic receptor antagonists such as tolterodine and oxybutanin with further examples from this class expected on the market. Therapeutics from novel pharmacological classes are expected to offer further improvements and in an upcoming edition of the Journal of Pharmacology & Experimental Therapeutics Uni
LeadDiscovery
13 Feb 04
Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on a number of novel approaches to the treatment of cancer including the development of caspase inhibitors; gene therapy approaches to the expression of TNF-alpha; an advanced monoclonal antibody; and a strategy to block XIAP. In addition new therapeutics for the treatment of rheumatoid
LeadDiscovery
13 Feb 04
According to WHO, there are some 130 million diagnosed diabetics in the world. The market for diabetes therapeutics is rising. Oral antidiabetic drugs, the leading class of drugs used to treat the disease, accounted for almost 63% of sales during this period, while sales of insulin stand at around 30%. Further increases are inevitable and the market for diabetes medications could exceed $20 billion by 2006. The largest unmet need in the diabetes market is improved delivery of insulin. Currently,
LeadDiscovery
13 Feb 04
This edition of "Emerging Drug Discovery Targets" features a potential approach to the treatment of COPD; Ligands' retinoic acid receptor agonist with appetite suppressive and insulin sensitizing properties; the use of HDAC inhibitors for the treatment of rheumatoid arthritis; Tamoxifen as a dual chemopreventative and anti-atherosclerosis treatment; and broad based inhibition of multidrug resistance proteins for improved cancer treatment. As usual we also provide updates on industrial advances a
LeadDiscovery
03 Feb 04
Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.
Jennifer McGinnis
.gif)
20 Jan 04
a Bristol based Biochemical Company, says it has invented a new sprayable antibacterial disinfectant agent, to be launched under the name of D-Stroy, that can kill the hospital superbug MRSA and TB.
Daisy Norman
.gif)
19 Jan 04
Obtaining a benefit from pharmaceutical R&D investment requires long-term planning and a consideration of how the commercial and technological environment in which the industry operates might change.
Dr Faiz Kermani
05 Jan 04
This edition of features new generation oncolytic viruses from Cell Genesys active against colorectal cancer cells; a p38 MAPK inhibitor for the treatment of rheumatoid arthritis from Fujisawa; data describing the anti-angiogenic activity of bisphosphonates in cancer models; a new JAK3 inhibitor from Pfizer for transplant rejection; and an integrin antagonist from Merck for the treatment of osteoporosis. As usual updates on industrial advances and licensing opportunities are provided.
LeadDiscovery
02 Jan 04
Pharmaceutical Education Associates' proud to present our 2nd Annual Pediatric Drug Development conference, slated for February 23-24, 2004 in Washington, D.C. Don't miss your chance to hear about the key issues impacting pediatric drug development today! For more information call us at 800-686-2276 visit www.pharmedassociates.com.
Feliz Casanova
18 Dec 03
Pharma NewsBytes selects out what LeadDiscovery considers as being some of the most interesting press releases to have appeared on their DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of Alzheimer's disease; advances in autoimmune diseases and inflammatory disorders; and news from the 26th Annual San Antonio Breast Cancer Symposium
LeadDiscovery
18 Dec 03
Transplantation immunotherapy commonly involves the use of azathioprine often combined with low doses of cyclosporine. Increased susceptibility to infection and severe toxicity represent serious adverse effects and a newer molecular target being investigated for the prevention of transplant rejection is Janus tyrosine kinase 3 (Jak3). Jak3 is this months "Target of the Month" from LeadDiscovery's and here they describe Pfizer's efforts to optimize inhibitors of this kinase
LeadDiscovery
16 Dec 03
Personality test experts People Maps return to offer candidates more invaluable advise about the use of personality profilers and their importance in the job interview process
Martin Gibbons
15 Dec 03
This comprehensive one-day training offers MSLs, their managers and those interested in a better understanding of the profession an overview of what the job entails, best practices and realistic ways to incorporate them into your own job. The training will focus on the components of a successful career as a MSL, as opposed to educating on individual therapeutic types.
Jennifer McGinnis
21 Nov 03
This edition of "Emerging Drug Discovery Targets" features a potent histone deacetylase inhibitor from Norvartis for the treatment of cancer, two new approaches to metabolic disorders and VEGFR-1 as a target for rheumatoid arthritis. As usual we also provide updates on industrial advances and licensing opportunities.
LeadDiscovery
19 Nov 03
The field of histone deacetylation continues to receive considerable interest principally due to the ability of histone deacetylase (HDAC) inhibitors to produce cytostatic activity in cancer, but more recently due to the role that this class has in other indications such as autoimmune disorders. Novartis researchers have now developed a HDAC inhibitor of greater anti-proliferative potency than that of SAHA, and which almost completely blocked the growth of human colon and lung cancer xenografts
LeadDiscovery
19 Nov 03
Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of rheumatoid arthritis; advances in anti-hyperlipemia therapeutics; and the termination of MK-0869 development for the treatment of depression
LeadDiscovery
04 Nov 03
It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition. This comprehensive report evaluates breaking drug discovery targets and therapeutic candidates for the treatment of this disease
LeadDiscovery
